A Case of Pancreatic Neuroendocrine Tumor G3 Which Responded Remarkably to Chemotherapy

Satoru NEBUYA; Shinji OE; Yoshikazu HARADA; Yusuke TAKEUCHI; Akitoshi YONEDA; Yudai KOYA; Koichiro MIYAGAWA; Yuichi HONMA; Michihiko SHIBATA; Masaru HARADA

doi:10.7888/juoeh.44.287

Satoru NEBUYA , Shinji OE, Yoshikazu HARADA, Yusuke TAKEUCHI, Akitoshi YONEDA, Yudai KOYA, Koichiro MIYAGAWA, Yuichi HONMA, Michihiko SHIBATA, Masaru HARADA

Author information

Satoru NEBUYA Corresponding author
Third Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan.
Shinji OE
Third Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan.
Yoshikazu HARADA
Department of Pathology and Cell Biology, School of Medicine, University of Occupational and Environmental Health, Japan.
Yusuke TAKEUCHI
Third Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan.
Akitoshi YONEDA
Third Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan.
Yudai KOYA
Third Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan.
Koichiro MIYAGAWA
Third Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan.
Yuichi HONMA
Third Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan.
Michihiko SHIBATA
Third Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan.
Masaru HARADA
Third Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan.

Keywords: neuroendocrine neoplasms (NENs), NET G3, NEC, streptozocin

JOURNAL FREE ACCESS

2022 Volume 44 Issue 3 Pages 287-292

DOI https://doi.org/10.7888/juoeh.44.287

Details

Abstract

Pancreatic neuroendocrine carcinoma (NEC) as classified in the World Health Organization (WHO) 2010 was reclassified in the WHO 2017 as either neuroendocrine tumor (NET) G3 or NEC. An accurate diagnosis based on the WHO 2017 classification is important in order treating this disease appropriately. We report a case diagnosed as NET G3 that responded remarkably well to treatment with streptozocin. The patient would likely not have received the streptozocin treatment if she had been diagnosed with NEC. The WHO 2017 classification is reasonable for the treatment of advanced pancreatic neuroendocrine neoplasms.

Corresponding author

Register with J-STAGE for free!